Novartis...Pfizer: Si es genérico es bueno.

A que la "marca" si es importante...














Novartis has signed an agreement to purchase Ebewe Pharma's speciality generic injectables business for €925m.

The deal will see Sandoz - Novartis' generic division and the second-largest generics company in the world - expand its generic oncology portfolio considerably.

"The addition of Ebewe Pharma's leading portfolio of oncology medicines fits our strategy and improves our ability to help cancer patients around the world by providing easier access to therapies. These medicines will remain the backbone of multi-drug treatments in the fight against cancer, one of the world's leading causes of death," said Dr Daniel Vasella, chairman and CEO of Novartis. "Ebewe Pharma will further strengthen our pipeline with many planned near-term launches."

Ebewe Pharma, an Austrian company, has built a lot of its success by developing value-added products such as advanced delivery devices and innovative package (eg Onco-Safe), rather than just pure generic versions of branded equivalents.

Ver mas...

Pfizer has entered into licensing agreements with two pharmaceutical companies in India, strengthening its position in emerging markets and significantly expanding its Established Products Business Unit's medicines portfolio.

Under the terms of the expanded agreements with Aurobindo Pharma, Pfizer has acquired rights to 55 solid oral dose products and 5 sterile injectable products for patients in more than 70 emerging market countries. These medicines include antibiotics and anti-infectives and cover a broad range of disease areas such as cardiovascular and central nervous system disorders. Pfizer plans to commercialise the 60 products in phases, tailoring its approach for different regions. Financial terms of the deal have not been disclosed.

Ver mas...